U.S. Oil and Gas Stock News

Lexicon Pharmaceuticals (LXRX) is back in focus after first quarter results showed revenue of US$21.1 million versus US$1.26 million a year earlier, along with a net loss of US$1.04 million compared with US$25.3 million. See our latest analysis for Lexicon Pharmaceuticals. The stock’s recent 1-day share price return fell 4.29% to US$2.23, while the 90-day share price return of 70.23% and 1-year total shareholder return of 316.67% indicate strong momentum following the earnings update,...

Earlier this week, Waste Management appointed longtime executive Tara Hemmer as Executive Vice President and Chief Operating Officer, while announcing the upcoming July retirement of Senior Vice President Rafael Carrasco and a realignment of the WM Healthcare Solutions business under President John Morris. By elevating its Chief Sustainability Officer to oversee the entire operating platform, Waste Management is tightly linking day-to-day operations with its recycling, renewable energy and...

ACADIA Pharmaceuticals Inc. reported first-quarter 2026 results, with revenue rising to US$268.06 million while net income fell to US$3.64 million, and reaffirmed full-year 2026 revenue guidance of US$1.22 billion to US$1.28 billion, including NUPLAZID and DAYBUE sales ranges. Alongside these results, ACADIA reiterated its focus on expanding NUPLAZID and DAYBUE and flagged upcoming phase 2 data for remlifanserin in Alzheimer’s disease psychosis, underscoring management’s emphasis on...

Why Rush Street Interactive (RSI) Is Back on Investors’ Radar Rush Street Interactive (RSI) has just delivered a quarter that set new records for revenue, net income, and adjusted EBITDA, with revenue up 41.1% year on year and full-year guidance raised above earlier expectations. See our latest analysis for Rush Street Interactive. The share price has pulled back slightly in the last week, with a 7 day share price return of a 3.5% decline and a 1 day move down 1.5%. However, momentum over...

Nu Holdings (NYSE:NU) opened Q1 2026 with total revenue of US$1.98 billion and basic EPS of US$0.18, setting a clear marker for its latest quarter at a share price of US$12.19. Over the past year, the company has seen revenue move from US$1.38 billion in Q1 2025 to US$1.98 billion in Q1 2026, while basic EPS moved from US$0.12 to US$0.18 over the same period, framing a steadily larger profit pool for shareholders. Taken together with trailing net income of US$3.18 billion and a reported net...

McGrath RentCorp (MGRC) has secured a new five year, US$725 million credit facility that replaces its prior US$650 million line. This financing move directly affects funding capacity and balance sheet flexibility. See our latest analysis for McGrath RentCorp. The new US$725 million facility comes as the share price has eased in the short term, with a 1 month share price return of down 3.15% and a 3 month share price return of down 5.01%. At the same time, the year to date share price return...

Recent stock performance context for KalVista Pharmaceuticals KalVista Pharmaceuticals (KALV) has drawn fresh attention after a strong share price move, with the stock up about 31% over the past month and roughly 79% over the past 3 months. See our latest analysis for KalVista Pharmaceuticals. That recent surge sits on top of a much stronger long-term picture, with a 1-year total shareholder return of 124.06% and a 3-year total shareholder return of 153.85%, signalling firm upward momentum...

Seritage Growth Properties Q1 2026 Earnings Snapshot Seritage Growth Properties (SRG) has opened Q1 2026 reporting season with recent revenue of US$4.6 million in Q4 2025 and basic EPS of US$0.11 loss per share, setting the tone for how investors will be weighing the latest numbers against past results. The company has seen quarterly revenue move from US$3.4 million in Q3 2024 to US$5.4 million in Q3 2025 and US$4.6 million in Q4 2025. Quarterly basic EPS has ranged from a loss of US$0.41 per...

Investors may be wondering whether Quaker Chemical at around US$137.99 is still offering value, or if most of the easy gains are already behind it. The stock is down about 6.5% over the last week and 1.3% over the last month, roughly flat year to date with a 0.7% decline, yet still up 31.1% over the past year after longer term declines of 31.4% over three years and 37.0% over five years. Recent coverage has focused on Quaker Chemical's position in the specialty chemicals sector and how...

NeoVolta (NEOV) has just posted another loss making quarter, with Q2 2026 revenue at US$4.6 million and a basic EPS loss of US$0.16, alongside net income excluding extra items of a US$5.5 million loss. The company has seen revenue move from US$0.6 million in Q1 2025 to US$6.7 million in Q1 2026, while quarterly EPS has ranged from a loss of US$0.03 to US$0.16 over that stretch. This has left investors focused on how quickly margins can tighten toward breakeven. See our full analysis for...

Q1 2026 headline results set the tone National Presto Industries (NPK) opened 2026 with Q1 revenue of US$118.6 million and basic EPS of US$0.93, putting fresh numbers on the table for investors weighing the recent move in the stock around US$137.98. The company has seen quarterly revenue range from US$103.6 million in Q1 2025 to US$163.9 million in Q4 2025, while basic EPS moved between US$0.72 and US$2.10 over the same period. This gives you a clear sense of how the top and bottom lines have...

Disc Medicine, Inc. reported a first-quarter 2026 net loss of US$63.5 million, with basic loss per share from continuing operations of US$1.65, while also preparing to present new data from multiple hematology programs at the European Hematology Association Congress. The upcoming RALLY-MF phase 2 and bitopertin data presentations at a major hematology meeting highlight how much of Disc Medicine’s story now hinges on clinical progress rather than current earnings. Next, we’ll examine how the...

Horizon Kinetics Holding (OTCPK:HKHC) Q1 2026 results in focus Horizon Kinetics Holding (OTCPK:HKHC) has followed up a volatile 2025 with Q1 2026 results that sit against a trailing 12 month backdrop of US$72.8 million in revenue and Basic EPS of US$0.34, after a year that also included a one off loss of US$33.7 million. Over recent periods, the company has seen quarterly revenue move from US$18.2 million in Q4 2024 to US$19.8 million in Q1 2025, then to US$17.9 million in Q3 2025 and US$17.0...

Cabot stock at a glance Cabot (CBT) has drawn fresh attention after recent trading left the stock at US$81. For investors, that price sits alongside a reported US$3,575.0m in revenue and US$281.0m in net income. See our latest analysis for Cabot. Recent trading has been choppy, with the share price down over 1 day and over the past week. However, a 30-day share price return of 8.83% and a year-to-date share price return of 20.81% sit alongside a 1-year total shareholder return of 8.39%,...

MoonLake Immunotherapeutics (MLTX) has cleared a key regulatory step by completing a final pre-BLA meeting with the FDA for sonelokimab in hidradenitis suppurativa, achieving alignment on efficacy, safety data inclusion, and submission timing. See our latest analysis for MoonLake Immunotherapeutics. Despite the recent pullback, with a 1-day share price return of 4.57% and a 30-day share price return of 4.31% both declining, MoonLake’s share price is still up 46.86% year to date, while the...

In the past quarter, Carrier Global reported Q1 2026 sales of US$5.3 billion and a 35% jump in global Commercial HVAC orders, powered by a very large increase in data center demand and new investments in AI-focused cooling technologies. At the same time, Carrier Ventures’ backing of advanced liquid cooling provider ZutaCore underlines how the company is tying its growth in data center orders to next‑generation infrastructure for high‑density AI workloads. Next, we’ll examine how this surge...

In early May 2026, TransMedics Group reported first-quarter 2026 results showing revenue of US$173.93 million, up from US$143.54 million a year earlier, but net income fell to US$7.32 million from US$25.68 million and diluted earnings per share from continuing operations declined to US$0.20 from US$0.70. The company also reiterated its full-year 2026 revenue guidance of US$727 million to US$757 million, signaling confidence in continued top-line expansion even as profitability compressed in...

Hess Midstream LP recently reported past first-quarter 2026 results, posting higher year-over-year revenue of US$390.1 million and net income of US$87.6 million, alongside steady operational throughput across most segments. The company also reaffirmed its full-year 2026 net income outlook of US$650 million to US$700 million, signalling confidence in its fee-based midstream model despite mixed volume trends in crude and water gathering. Next, we will examine how reaffirmed 2026 earnings...

Earlier this month, Stifel Financial Corp. launched a Project Finance platform aimed at funding energy and infrastructure projects using proven commercial technologies, offering development loans, construction-to-term loans, interest rate swaps, depository services, and investment banking advisory support. This expansion builds on Stifel’s newer Energy Tech and Deep Tech teams, signaling a broader push to serve the evolving global energy and infrastructure ecosystem through integrated...

Marten Transport stock moves after recent performance data Marten Transport (MRTN) has drawn fresh attention after recent performance data highlighted both its current valuation and its business mix across truckload, dedicated, and brokerage operations for temperature controlled freight. See our latest analysis for Marten Transport. Recent trading has been a mixed picture, with Marten Transport’s 30 day share price return of 12.87% and year to date share price return of 35.55% contrasting...

In May 2026, CorMedix Inc. reported first-quarter 2026 revenue of US$127.43 million and net income of US$38.6 million, and raised its full-year 2026 net revenue guidance to a range of US$325 million to US$345 million. The quarter also featured positive Phase III topline results for REZZAYO in prophylaxis and continued advancement of DefenCath and taurolidine/heparin programs, underscoring how CorMedix is tying commercial growth to late-stage pipeline progress. Next, we’ll explore how...

Earlier this month, Paymentus Holdings reported first-quarter 2026 results with revenue of US$358.44 million and net income of US$20.88 million, raised its full-year 2026 revenue guidance to US$1.43 billion–US$1.44 billion, and issued second-quarter revenue guidance of US$340 million–US$350 million. The company also introduced its patented Billeo™ and BillWallet® offerings and broader AI-native Service Commerce platform, aiming to turn bills and other transactional documents into...

Wondering whether CorVel at US$57.11 is starting to look like value or still has risk priced in? This article walks through what the current market price may be implying. The stock is up 1.3% over the past month but has fallen 13.1% year to date and declined 49.8% over the past year. These moves can change how you think about both upside potential and downside risk. Recent attention around CorVel has focused on its role within the US healthcare sector and how investors are reassessing...

Brookfield Business Corporation recently reported first-quarter 2026 results showing sales of US$6,436 million and net income of US$40 million, both lower than a year earlier, while its board affirmed a quarterly dividend of US$0.0625 per Class A share payable on June 30, 2026. Over the life of its current repurchase authorization announced in August 2025, the company has bought back 2,100,000 shares for US$72 million, effectively pairing capital returns via dividends with completed, though...